HENLIUS News

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024

Oct 2 04:36 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT -AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OFPERTUZUMAB BIOSIMILAR HLX11 (RECOMBINANT ANTI-HER2DOMAIN II HUMANIZED MONOCLONAL ANTIBODY INJECTION) FORTHE NEOADJUVANT THERAPY OF HER2-POSITIVE, HR-NEGATIVEEARLY OR LOCALLY ADV

Sep 27 06:00 ET

HENLIUS: INTERIM REPORT 2024

Sep 26 04:30 ET

HENLIUS: JOINT ANNOUNCEMENT -PROGRESS UPDATE IN RELATION TOTHE PRE-CONDITIONAL PRIVATISATIONOF HENLIUS BY FOSUN NEW MEDICINEBY WAY OF MERGER BY ABSORPTION OF HENLIUS

Sep 23 08:07 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - SERPLULIMAB INJECTION (CHINESE TRADE NAME: HANSIZHUANG)RECEIVED POSITIVE OPINION FROM THE COMMITTEE FORMEDICINAL PRODUCTS FOR HUMAN USE (CHMP)OF THE EUROPEAN MEDICINES AGENCY (EMA)

Sep 20 10:30 ET

HENLIUS: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TOCONTINUING CONNECTED TRANSACTIONS UNDER THEBUSINESS TRAVEL MANAGEMENT SERVICES AGREEMENT ANDGENERAL PROCUREMENT FRAMEWORK AGREEMENT

Sep 11 06:00 ET

HENLIUS: CONTINUING CONNECTED TRANSACTIONS - (1) BUSINESS TRAVEL MANAGEMENT SERVICES AGREEMENTAND(2) GENERAL PROCUREMENT FRAMEWORK AGREEMENT

Sep 5 05:07 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Sep 4 05:01 ET

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024

Sep 4 04:43 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Sep 3 05:17 ET

HENLIUS: Disclosure of Dealings under Rule 22 of the Takeovers Code

Sep 2 04:48 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE CLINICAL TRIAL OFPEMBROLIZUMAB BIOSIMILAR HLX17 (RECOMBINANTHUMANISED ANTI-PD-1 MONOCLONAL ANTIBODY INJECTION)APPROVED BY NATIONAL MEDICAL PRODUCTSADMINISTRATION

Sep 2 04:45 ET

HENLIUS: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024

Aug 26 06:37 ET

HENLIUS: CHANGE OF JOINT COMPANY SECRETARY,PROCESS AGENT AND AUTHORISED REPRESENTATIVE

Aug 26 06:30 ET

HENLIUS: JOINT ANNOUNCEMENT -(1) REVISED PROPOSED PRE-CONDITIONAL PRIVATISATIONOF HENLIUS BY FOSUN NEW MEDICINEBY WAY OF MERGER BY ABSORPTION OF HENLIUS(2) PROPOSED WITHDRAWAL OF LISTINGAND(3) POSSIBLE DISCLOSEABLE TRANSACTION OF FOSUN PHARMA

Aug 23 09:15 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT -HLX02 (TRASTUZUMAB FOR INJECTION, PRODUCT NAME IN CANADA:ADHEROZA) FOR THE TREATMENT OF EARLY BREAST CANCER,METASTATIC BREAST CANCER AND METASTATIC GASTRIC CANCERAPPROVED BY THE HEALTH CANADA

Aug 22 05:43 ET

HENLIUS: JOINT ANNOUNCEMENT - PROGRESS UPDATE ON THE PRE-CONDITIONAL PRIVATISATIONOF HENLIUS BY FOSUN NEW MEDICINEBY WAY OF MERGER BY ABSORPTION OF HENLIUS

Aug 14 07:19 ET

HENLIUS: DATE OF BOARD MEETING

Aug 14 04:59 ET

HENLIUS: VOLUNTARY ANNOUNCEMENT -THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 2 CLINICAL TRIALOF HLX53 (ANTI-TIGIT FC FUSION PROTEIN) IN COMBINATIONWITH HANSIZHUANG (SERPLULIMAB INJECTION) AND HANBEITAI(BEVACIZUMAB INJECTION) FOR THE FIRST-LINE TREATMENTOF LOCALLY A

Aug 8 06:29 ET

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024

Aug 5 04:34 ET